Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
StemRegenin-1 Expanded vs Unmanipulated UCB Transplantation
NCT02765997Phase 2Withdrawn
- Sponsor
- Masonic Cancer Center
- Start
- Apr 2017
- Primary completion
- Jun 2020
- Modality
- Hematopoietic Stem Cells
- Countries
- 1
01
Overview
A Phase 2 trial of spanlecortemlocel in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myeloid leukemia (CML), myelodysplastic syndrome (MDS), sponsored by Masonic Cancer Center. Planned start Apr 2017; status: withdrawn.
02
Drugs
spanlecortemlocel
03
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)chronic myeloid leukemia (CML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT02765997.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02765997.